Linked Life Data

12213288

Source:http://linkedlifedata.com/resource/pubmed/id/12213288

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-9-5
pubmed:abstractText
The survival of patients affected by cutaneous melanoma has improved dramatically in the last 10 years, because of earlier diagnosis. Despite this, the therapeutic results obtained in metastatic melanoma (MM) are very disappointing due to its poor responsiveness to cytotoxic agents. In this type of solid tumor, tumor chemosensitivity assays have been suggested to be an important tool to predict clinical responsiveness to therapy. Metastatic melanoma cells (MMCs) were obtained from subcutaneous melanoma metastases of five patients and cultured for several consecutive passages. An immunofluorescence and an electron microscopic study were performed in order to establish the ultrastructural and physiopathological features of MMCs. A sulphorodamine-B test was used to measure in vitro sensitivity of MMCs to temozolomide, cisplatin, vindesine, taxol and interpheron alpha-2a. Following a 72 h exposure, maximum activity was obtained with vindesine (median inhibitory concentration, IC(50), 0.23 nM) and taxol (median IC(50) 0.31 nM). Cisplatin median IC(50) values were higher (4.6 microM) than taxol and vindesine, but still in the range of clinically achievable plasma concentrations. Temozolomide inhibited cell proliferation only at very high concentrations (median IC(50) 228 microM). No significant cell growth inhibitory effects (<or=25%) were observed with interferon alpha-2a concentrations up to 8000 IU/ml. MMCs expressed progression markers typical of cutaneous metastatic melanoma and showed poor sensitivity in vitro to most anticancer drugs tested, including temozolomide.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0304-3835
pubmed:author
pubmed:issnType
Print
pubmed:day
5
pubmed:volume
186
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
183-92
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:12213288-Antineoplastic Agents, pubmed-meshheading:12213288-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12213288-Cells, Cultured, pubmed-meshheading:12213288-Cisplatin, pubmed-meshheading:12213288-Dacarbazine, pubmed-meshheading:12213288-Dose-Response Relationship, Drug, pubmed-meshheading:12213288-Fluorescent Antibody Technique, Indirect, pubmed-meshheading:12213288-Humans, pubmed-meshheading:12213288-Immunophenotyping, pubmed-meshheading:12213288-Inhibitory Concentration 50, pubmed-meshheading:12213288-Interferon-alpha, pubmed-meshheading:12213288-Melanoma, pubmed-meshheading:12213288-Microscopy, Electron, pubmed-meshheading:12213288-Neoplasm Metastasis, pubmed-meshheading:12213288-Paclitaxel, pubmed-meshheading:12213288-Recombinant Proteins, pubmed-meshheading:12213288-Time Factors, pubmed-meshheading:12213288-Tumor Cells, Cultured, pubmed-meshheading:12213288-Vindesine
pubmed:year
2002
pubmed:articleTitle
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.
pubmed:affiliation
Department of Dermatological Sciences, University of Florence, Via Degli Alfani n.37, 50121 Florence, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't